• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    6/7/24 1:35:20 PM ET
    $ABBV
    $GILD
    $LLY
    $NVCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    NVO PUT SWEEP BULLISH 07/19/24 $135.00 $44.5K 2.0K 947
    LLY CALL TRADE BEARISH 06/14/24 $905.00 $45.0K 53 471
    UNH CALL TRADE BEARISH 07/19/24 $510.00 $88.5K 919 322
    ABBV CALL SWEEP BULLISH 06/14/24 $167.50 $50.8K 2.3K 242
    SMMT CALL TRADE BULLISH 07/19/24 $4.00 $26.6K 5.5K 76
    SAVA CALL TRADE BEARISH 06/20/25 $35.00 $38.2K 780 71
    NVCR CALL TRADE BEARISH 01/17/25 $15.00 $45.5K 1.0K 54
    GILD PUT SWEEP BEARISH 06/20/25 $65.00 $30.0K 1.1K 53
    TMO CALL TRADE BEARISH 09/20/24 $600.00 $32.6K 142 34
    VKTX CALL TRADE BULLISH 01/16/26 $80.00 $36.6K 127 25

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For NVO (NYSE:NVO), we notice a put option sweep that happens to be bullish, expiring in 42 day(s) on July 19, 2024. This event was a transfer of 273 contract(s) at a $135.00 strike. This particular put needed to be split into 39 different trades to become filled. The total cost received by the writing party (or parties) was $44.5K, with a price of $163.0 per contract. There were 2089 open contracts at this strike prior to today, and today 947 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option trade with bearish sentiment. It expires in 7 day(s) on June 14, 2024. Parties traded 280 contract(s) at a $905.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $161.0 per contract. There were 53 open contracts at this strike prior to today, and today 471 contract(s) were bought and sold.

    • Regarding UNH (NYSE:UNH), we observe a call option trade with bearish sentiment. It expires in 42 day(s) on July 19, 2024. Parties traded 100 contract(s) at a $510.00 strike. The total cost received by the writing party (or parties) was $88.5K, with a price of $885.0 per contract. There were 919 open contracts at this strike prior to today, and today 322 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a call option sweep that happens to be bullish, expiring in 7 day(s) on June 14, 2024. This event was a transfer of 164 contract(s) at a $167.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $50.8K, with a price of $310.0 per contract. There were 2311 open contracts at this strike prior to today, and today 242 contract(s) were bought and sold.

    • Regarding SMMT (NASDAQ:SMMT), we observe a call option trade with bullish sentiment. It expires in 42 day(s) on July 19, 2024. Parties traded 70 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $380.0 per contract. There were 5564 open contracts at this strike prior to today, and today 76 contract(s) were bought and sold.

    • Regarding SAVA (NASDAQ:SAVA), we observe a call option trade with bearish sentiment. It expires in 378 day(s) on June 20, 2025. Parties traded 49 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $38.2K, with a price of $780.0 per contract. There were 780 open contracts at this strike prior to today, and today 71 contract(s) were bought and sold.

    • For NVCR (NASDAQ:NVCR), we notice a call option trade that happens to be bearish, expiring in 224 day(s) on January 17, 2025. This event was a transfer of 54 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $45.5K, with a price of $844.0 per contract. There were 1072 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold.

    • Regarding GILD (NASDAQ:GILD), we observe a put option sweep with bearish sentiment. It expires in 378 day(s) on June 20, 2025. Parties traded 47 contract(s) at a $65.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $640.0 per contract. There were 1167 open contracts at this strike prior to today, and today 53 contract(s) were bought and sold.

    • Regarding TMO (NYSE:TMO), we observe a call option trade with bearish sentiment. It expires in 105 day(s) on September 20, 2024. Parties traded 15 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $2174.0 per contract. There were 142 open contracts at this strike prior to today, and today 34 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option trade that happens to be bullish, expiring in 588 day(s) on January 16, 2026. This event was a transfer of 21 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $36.6K, with a price of $1743.0 per contract. There were 127 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $GILD
    $LLY
    $NVCR

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    3/10/2026$180.00Buy
    Jefferies
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    Novo Nordisk A/S
    $NVO
    2/24/2026Overweight → Neutral
    Analyst
    More analyst ratings

    $ABBV
    $GILD
    $LLY
    $NVCR
    SEC Filings

    View All

    Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/10/26 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UnitedHealth Group Incorporated filed SEC Form 8-K: Regulation FD Disclosure

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    3/9/26 4:33:13 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Meyer James claimed ownership of 5,891 shares (SEC Form 3)

    3 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/10/26 4:07:46 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Chairman & CEO Casper Marc N exercised 4,000 shares at a strike of $309.63 and sold $2,059,261 worth of shares (4,000 units at $514.82) (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/9/26 4:39:01 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $ABBV
    $GILD
    $LLY
    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Gilead Sciences with a new price target

    Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00

    3/10/26 8:40:41 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novo Nordisk A/S downgraded by TD Cowen with a new price target

    TD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00

    3/10/26 8:39:23 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Novo Nordisk A/S from Underweight to Equal-Weight and set a new price target of $40.00

    3/3/26 8:17:03 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ABBV
    $GILD
    $LLY
    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

    New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC

    3/10/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

    ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels.  No serious adverse events were reported1Data support continued development of ABBV-295 as a potentially differentiated treatment for chronic weight management, with a non-incretin-based mechanism of action NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluati

    3/9/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Participate at Upcoming Investor Conferences

    SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.  Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern

    3/5/26 4:03:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    Financials

    Live finance-specific insights

    View All

    Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

    Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advanc

    2/26/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei

    2/25/26 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on March 17, 2026, to all shareholders of record of UNH common stock as of the close of business March 9, 2026. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health

    2/25/26 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    $ABBV
    $GILD
    $LLY
    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/12/24 5:54:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care